Case | Previous therapies | Surgery | Anti-HER2 therapy | Response | PFS | Main ADRs |
1 | Laser therapy; radiotherapy; imiquimod; photodynamic therapy |
|
|
| First-line therapy: 36 months Second-line therapy: 14 months | G3: neutropenia |
2 | Cisplatin; pelvic radiotherapy |
| Weekly paclitaxel plus weekly trastuzumab for 5 months | PR | 10 Months | G2: anemia, onychopathy. |
3 | Laser vaporization; testosterone propionate |
|
| 1. CR than PD (brain) during trastuzumab | 12 Months until encephalic PD 16 Months until liver and bone PD | G1: fatigue, constipation, nausea, anemia and alopecia G2: neurotoxicity |
4 | Steroids, hyaluronic acid, tocopherol, anti-fungal, for vulvar lichen (misdiagnosed) Topical treatment with imiquimod (VPD) |
|
| Objective local response and subjective relief in symptoms | Not evaluable | G2: neurotoxicity |
ADR, adverse drug reaction; CR, complete response; G, toxicities grade according to NCI CTCAE v4.0; HER2, human epidermal growth factor receptor 2 ; PD, progression disease; PFS, progression free survival defined as the time from treatment start to date of radiological or clinical progression; PR, partial response.